Press Releases
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- Atu027 update: progression into Phase IIa
- Silence Therapeutics sponsors number one ranked US chess player
- Notice of General Meeting and Annual Report
- Final Results
- Directorate Change
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Result of EGM
- Scientific and Company Background
- Placing and Share Consolidation
- Exercise of warrants
- Business Update
- Holding in Company
- Exercise of warrants
- Appointment of Chief Medical Officer
- Total Voting Rights
- Total Voting Rights
- Holding in Company
- Option Exercise
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Option Exercise and TVR
- Directors’ dealings
- Subscription of New Ordinary Shares and conversion of £1m loan note
- Proposed Placing
- Adviser Change of Name
- 2 US patents allowed Nov 2012
- Appointment of Tim Freeborn Finance Director
- Exercise of Warrants 15 October 2012
- Interim Results for the Six Months Ended 30 June 2012
- Notice of Results
- Michael Khan Appointed Chief Medical Adviser to Silence Therapeutics
- Holding in Company
- Significant pre-clinical data in acute lung injury
- Holding in Company
- Holding in Company
- Silence Therapeutics sign collaboration with MiReven
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- SLN Options and Board Changes
- Results of General Meeting
- Results of Open Offer
- Holding in Company
- Holding in Company
- Project Speaker Subscription Open Offer Announcement
- Silence Subscription and Open Offer Announcement – Revised
- Silence Respond to Press Speculation
- Silence Therapeutics Announces Safe and Effective Dose Successfully Identified in Phase I study of Atu027
- Silence Announce New Data from Phase I Study of Atu027 RNAi Therapy
- Publication of 2011 Annual Report and Notice of AGM
- Silence’s partner, Quark Pharmaceuticals, extends Pfizer agreement to develop RNAi compound
- Unaudited Preliminary Results for the Year ended 31 December 2011
- Silence Therapeutics Forms Scientific Advisory Board and Forms Two New Research Collaborations
- Notification of Preliminary Results
- Silence and other opponents of Tuschl I patent succeed in limiting scope and ambiguity in patent
- Tony Sedgwick appointed new Chief Executive Officer of Silence Therapeutics
- Holding in Company
- Holding in Company
- Silence Therapeutics signs collaboration with miRagen Therapeutics to evaluate delivery of novel microRNA-based therapeutics
- Research and Development Collaboration Update
- Total Voting Rights
- Additional Listing
- Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
- Silence Therapeutics signs siRNA delivery collaboration with top 10 pharma company
- Silence Therapeutics announces positive outcome from oral hearing at the European Patent Office
- Silence Therapeutics provides corporate and development update
- Silence Therapeutics signs collaboration with Mirna Therapeutics to evaluate delivery of novel microRNA therapeutics
- Grant of Options
- Directors’ share purchases
- Silence Therapeutics signs siRNA delivery collaboration with top 10 pharma company
- Appointment of Chief Business Officer
- Interim Results for the Six Months Ended 30 June 2011
- Appointment of Chief Executive Officer
- Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
- Notice of Results
- Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics
- Silence Therapeutics to Present at Upcoming Investor Conferences
- Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
- Group Reorganisation and Board Changes
- Holding in Company
- Results of Annual General Meeting
- Silence Therapeutics’ Atu027 Demonstrates Promising Antitumor Activity in Phase I Study Presented at ASCO
- Silence Therapeutics Post-Fundraising Update
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Publication of 2010 Annual Report and Notice of AGM
- Silence Therapeutics to Present New Data from Phase I Study with Atu027 at 2011 ASCO Annual Meeting
- Holding in Company
- Holding in Company
- Holding in Company
- Silence Therapeutics Result of General Meeting
- Silence Therapeutics Result of Placing and Open Offer
- Grant of options and warrants
- Holding in Company
- Silence Therapeutics Issued Japanese Patent Covering Its Core RNA Interference (RNAi) Technology
- Silence Announces Financing
- Silence 2010 Full Year Results
- Holding in Company
- Financial Circular April 2011
- Silence Therapeutics’ Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
- Silence Therapeutics’ Partner Quark Pharmaceuticals Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema
- Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
- Silence Therapeutics to Present at 13th Annual BIO CEO & Investor Conference
- Termination of Offer Period
- Silence Therapeutics Provides Year-end Update
- Holding in Company
- Silence Therapeutics’ Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
- Silence Therapeutics Receives Comprehensive Protection for RNAI Structural Modification Technology in Single European Patent
- Interim Results for the Six Months Ended 30 June 2010
- Change of Nomad
- Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
- Potential Offer
- Silence Therapeutics’ Partner Quark Signs Exclusive Option Agreement with Novartis for Development and Commercialisation of QPI-1002
- Change of Auditor and Notice of Interim Results
- Silence Therapeutics Adds New Patent to Industry Leading Structural Modification Intellectual Property Portfolio
- Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
- Holding in Company
- Silence Therapeutics Expands RNAi Structural Modification IP Portfolio with Issuance of New U.S. Patent
- All resolutions passed at Annual General Meeting
- Silence Therapeutics Announces Issuance of New U.S. Patent Broadly Covering Methods for Enhancing Silencing Activity of RNAi Therapeutics
- Silence Therapeutics to Present at Upcoming Investor Conferences
- Silence Therapeutics Appoints New Vice President of Research
- Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
- Silence Therapeutics Plc Unaudited Preliminary Results for the Year Ended 31 December 2009
- Notification of Results
- Silence Therapeutics and AstraZeneca Extend siRNA Delivery Collaboration
- Silence Therapeutics Appoints Max Herrmann as Chief Financial Officer
- Silence Therapeutics Executes Strategic Plan to Optimize and Integrate Technologies and Assets from Intradigm Merger
- Holding in Company
- Silence Therapeutics and Dainippon Sumitomo Expand siRNA Delivery Collaboration
- Silence Therapeutics plc Announces Changes to Management and the Board of Directors
- Director’s Dealings
- Jerry Randall has been appointed Senior Independent Director
- Notification of Results
- Silence Therapeutics Receives Notice of Allowance for RNA Interference (RNAi) Patent Covering Novel Cancer Target
- Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
- Issued share capital – total voting rights
- Holding in Company
- Silence Therapeutics announces completion of merger with Intradigm Corporation and issue of new shares
- All resolutions passed at Extraordinary General Meeting
- Posting of the Admission Document to Shareholders
- Admission Document
- Silence Therapeutics to merge with Intradigm Corp to create leading RNAi therapeutics company
- AGM announcement
- Full Notice of AGM and Proxy Form
- Notice of AGM
- Silence Therapeutics’ core patent upheld by the European Patent Office
- Interim Results for the Six Months Ended 30 June 2009
- Merger discussions
- Notification of Results
- Holding in Company
- Silence Therapeutics signs siRNA delivery collaboration with Dainippon Sumitomo Pharma
- Holding in Company
- Issue of shares pursuant to exercise of options
- Silence Therapeutics publishes 2008 Annual report and Accounts
- Silence announces dosing of first patient in Atu027 cancer trial
- Silence receives approval to commence Phase I clinical trial with Atu027
- Silence issues Unaudited Preliminary Results for the year ended 31 December 2008
- Notification of Results
- Holding in Company
- Holding in Company
- Silence Therapeutics announces its successful opposition to second European Patent in Kreutzer-Limmer patent family
- Holding in Company
- Holding in Company
- Total Voting Rights
- Change of address
- European Patent Office grants Silence Therapeutics’ Patent on Target for Lead Compound Atu027
- Gartmore takes significant stake in Silence Therapeutics plc
- Silence Therapeutics’ partner Quark initiates next stage of clinical trials on DGF
- Unaudited preliminary results 2008
- Total Voting Rights
- Holding in Company
- Silence Therapeutics’ position is strengthened after European Patent Office revokes competitor RNA interference patent in its entirety
- Grant of Options
- Silence Therapeutics to make regulatory filing to take lead cancer therapy Atu027 into the clinic
- Exercise of options by staff
- Silence Therapeutics publishes comprehensive research showing that its lead candidate Atu027 inhibits cancer progression
- United States Patent and Trademark Office grants Silence Therapeutics Core RNAi Patent
- Holding in Company
- Holding in Company
- Silence Therapeutics announces Directors share purchases
- Silence Therapeutics announces Directors share purchases
- Silence Therapeutics announces Directors share purchases
- AGM Statement 2008
- Holding in Company
- European Patent Office raises serious concerns about legal validity of fundamental RNA interference patent
- Grant of Options
- Notice of AGM to be held on October 17 2008
- Interim Results for the Six Months Ended 30 June 2008
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
- Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial
- Silence Therapeutics Patent Update
- Holding in Company
- Holding in Company
- Timing of Annual General Meeting and of Interim Results Announcement
- European Patent Office issues notice of intent to grant patent for lead product
- Silence Therapeutics Announces Successful Opposition of Glover Patent
- Silence Therapeutics Announces Board Changes
- Holding in Company
- Silence announces FDA grants IND to Quark for AtuRNAi based siRNA product
- Holding in Company
- Holding in Company
- Silence Therapeutics to Present at Upcoming Biotechnology Industry Conferences
- Holding in Company
- Holding in Company
- Holding in Company
- Jeff Vick, CEO of Silence Therapeutics to Present at Rodman and Renshaw’s 5th Annual Global Healthcare Conference
- Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
- Silence Therapeutics announces Directors share purchases
- Silence Therapeutics announces Directors share purchases
- Silence Therapeutics plc announces its Preliminary Unaudited Results for the year ended 31 December 2007
- Holding in Company
- Holding in Company
- The Preliminary Unaudited Results for the year ended 31 December 2007 will be announced on 27 March 2008
- Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
- Holding in Company
- Holding in Company
- Holding(s) in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Share issue
- Share price movement
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Silence Therapeutics Appoints Financial Adviser and Broker and Nominated Adviser
- Silence Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
- Silence Therapeutics plc announces that a 2nd siRNA therapeutic based upon its unique proprietary chemistry has moved into clinical development
- Holding in Company
- Holding in Company
- Total Voting Rights~
- Silence Therapeutics to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
- Holding in Company
- Holding in Company
- Holding in Company
- Total Voting Rights~
- Exercise of options
- Directors dealings
- Interim Results for the Six Months Ended 30 June 2007
- Silence Therapeutics RNAi Lead Compound Atu027 Successfully Completes 28-Day Toxicology Studies
- Notice of Interim Results
- Holding in Company
- Holding in Company
- Holding in Company
- Holding in Company
- Compliance with AIM Rule 26
- Holding in Company
- Holding in Company
- 9 August 2007 (am) Holding in Company
- 9 August 2007 (pm) Holding in Company
- Result of AGM
- Holding in Company
- Total Voting Rights
- Silence Therapeutics And Quark Pharmaceuticals Expand Strategic Licensing Agreement
- Holding in Company
- Silence Therapeutics strengthens Management Team with the appointment of CEO
- Holding in Company
- Holding in Company
- Holding in Company
- Notice of Annual General Meeting
- Silence Therapeutics signs siRNA collaboration with AstraZeneca to develop Novel Respiratory Therapeutics
- Exercise of options by staff
- Exercise of options by staff
- Annual Report and Accounts 2006 and Annual General Meeting
- Total voting rights
- Holding in Company
- Holding in Company
- Silence Therapeutics to Present at Piper Jaffray 2nd Annual Healthcare Conference
- Exercise of options by staff
- Holding in Company
- Holding in shares
- Holdings in shares
- Holing in Company
- Holdings in shares
- Holdings in shares
- Exercise of options by staff
- Holding in shares
- Major Shareholder
- Exercise of options by staff
- Total Voting Rights
- EGM Statement
- Notification of share purchase by SR Pharma Chairman
- Grant of Options
- Share issue – staff options
- SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry
- Notice of Extraordinary General Meeting
- SR Pharma announces Preliminary Unaudited 2006 Results
- Extraordinary General Meeting
- SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry
- Holding in Company – Cantor Fitzgerald
- Holding in company – Man Financial Ltd
- Holding in Company
- SR Pharma – RNAi Technology Briefing
- Holding in company – Man Financial Ltd
- Commencement of clinical trials by licence partner
- SR Pharma plc Announces the Successful Completion of Additional Toxicology Studies for its Systemically Delivered RNAi Compound
- Holding in company – Fidelity
- SR Pharma granted Core RNAi patent by the European Patent Office
- SR Pharma plc Announces Superior Theraupeutic Efficcacy of Atu027 RNAi in Pre-Clinical Models of Pancreatic Cancer Compared to Gemcitabine® (pdf).
- Grant of Options
- Share Issue
- Placing of Shares
- Holdings in Company
- SR Pharma plc Announces the Successful Completion of Toxicology Studies for it’s Systematically Delivered RNAi Product Candidate Atu027
- Placing of Shares
- Holding in Company – Fidelity
- Holding in Company
- Holding in Company – Man Financial
- Holding in company – Man Financial Ltd
- SR Pharma plc to Receive Milestone Payments of up to US$95 Million (~£50 Million) from Pfizer as a Result of a Sublicensing Deal
- Holding in Company AIM Real fund holding
- Holding in Company Artemis shares
- SR Pharma plc Annual Report for the year ended 2005
- SR Pharma plc welcomes the European Patent Office decision to limit the scope of Kreutzer-Limmer RNAi Patent claim
- SR Pharma plc establishes GMP production with partners for its lead RNAi therapeutic product, Atu027
- Conversion of Warrants
- SR Pharma plc announces two key scientific publications on therapeutic RNAi in Gene Therapy
- SR Pharma plc announces Licence with Merck & Co
- SR Pharma plc – Issue and Admission of Shares (pdf).
- SR Pharma plc – Issue and Admission of Shares
- Major shareholders following placing
- Major shareholders following completion of acquisition of Atugen AG
- Result of EGM
- SR Pharma plc
- SR raises £10 million from Institutional Placing and Strategic Investment
- Annual General Meeting Statement
- Acquisition of Atugen AG
- SR Pharma to acquire Atugen
- Annual General Meeting
- SR Pharma plc results for the year ended 31 December 2004
- SR Pharma teminates merger discussions to progress aquisition of a European biotechnology company
- Holding in Company
- Holding in Company
- Extraordinary General Meeting
- Extraordinary General Meeting
- Holding in Company
- Holding in Company